urolithin D
6H-dibenzo[b,d]pyran-6-one, 3,4,8,9-tetrahydroxy-
Identification
| Name | urolithin D |
| CAS Number | 131086-98-1 |
| FDA UNII | Search |
| Molecular Formula | C13 H8 O6 |
| Molecular Weight | 260.20196000 |
| Nikkaji Number | J403.505D |
Regulatory
Physical Properties
| Assay | 95.00 to 100.00 |
| Food Chemicals Codex Listed | No |
| Boiling Point | 634.10 °C. @ 760.00 mm Hg (est) |
| Flash Point | 487.00 °F. TCC ( 253.00 °C. ) (est) |
| logP (o/w) | 0.919 (est) |
| Soluble in | water, 5374 mg/L @ 25 °C (est) |
No sensory data available
Safety Information
| Oral/Parenteral Toxicity | Not determined |
| Dermal Toxicity | Not determined |
| Inhalation Toxicity | Not determined |
GHS Classification
['GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)', 'GHS Label elements, including precautionary statements']
Safety in Use
| Category | natural substances and extractives |
| Recommendation for urolithin D usage levels up to | not for fragrance use. |
| Recommendation for urolithin D flavor usage levels up to | not for flavor use. |
No supplier data available
Potential Uses
Natural Occurrence
Synonyms
6H-
dibenzo(b,d)pyran-6-one, 3,4,8,9-tetrahydroxy-
6H-
dibenzo[b,d]pyran-6-one, 3,4,8,9-tetrahydroxy-
3,4,8,9-
tetrahydroxy-6H-benzo[c]chromen-6-one
3,4,8,9-
tetrahydroxy-benzo[c]chromen-6-one
3,4,8,9-
tetrahydroxybenzo[c]chromen-6-one
PubMed:
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells.
PubMed:
Pilot walnut intervention study of urolithin bioavailability in human volunteers.
PubMed:
Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells.
PubMed:
The influence of pomegranate by-product and punicalagins on selected groups of human intestinal microbiota.
PubMed:
Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans.